Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Shabadi N, Prashanth Kumar NK, Prakash B, Kulkarni P, Narayana Murthy MR
Introduction In the context of changing over from an intermittent treatment regimen to a daily regimen, it becomes crucial to understand the impact of a daily regimen on the treatment process and outcome. It enables health professionals to strengthen strategies, to enhance the qu…
Xueyi Chen, Oscar J Nino-Meza, Mona O. Sarhan, Bhavatharini Arun, Byeonghoon Jeon, et al.
…dicted tissue exposures which were used to design optimized regimens (Fig.1).Figure 1.Study design. Dynamic positron emission tomography (PET) was performed using radioanalogs of antibiotics (18F-pretomanid, 18F-sutezolid, 18F-linezolid and 76Br-bedaquiline) active against MDR st…
Rashmi Ratnam, Parul Jain, Ram Awadh Singh Kushwaha, Amita Jain, Urmila Singh, et al.
…the World Health Organization (WHO) recommends two all-oral regimens for rifampicin-resistant (RR), multidrug-resistant (MDR), and extensively drug-resistant (XDR) TB: a longer M/XDR-TB regimen (18–20 months) and a shorter bedaquiline-containing MDR/RR-TB regimen (9–11 months). T…
Gunar Günther, Lorenzo Guglielmetti, Claude Leu, Christoph Lange, Frank van Leth, et al.
…berculosis drugs and calculated cost of drugs and treatment regimens at major tuberculosis treatment centers in countries of the World Health Organization (WHO) European region. Results are stratified by middle and high-income countries. Results Overall, 43 treatment centers in 4…
Zarir Udwadia, Jennifer Furin
…n it comes to rolling out bedaquiline (BDQ)-based, all-oral regimens for drug-resistant forms of tuberculosis (DR-TB). India is home to the largest population of people living with DR-TB in the world,[2] and improving access to innovative diagnostic and therapeutic approaches is …
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…eatment failure, and loss of follow-up) related to all oral regimens containing bedaquiline and or delamanid in patients with MDR-TB. Method: This was a narrative review to summarize the role of the BPaL regimen to manage highly DR-TB patients. Results: The six months of BPaL reg…
J. A. M. Raaijmakers, Sandra Salillas, Rob E. Aarnoutse, Elin M. Svensson, Lindsey te Brake, et al.
…macodynamics were monitored throughout the experiment. Both regimens led to sustained bacterial killing (both intracellular and extracellular) throughout the experiment. No difference in kill rate was observed between the two therapies. The extracellular kill rate for the 3-drug …
Banurekha Velayutham, M S Jawahar, Chandrasekaran Padmapriyadarsini
…ence to our paper entitled ‘4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India – a randomised clinical trial’ in the letter ‘False equivalence of four month and six-month ATT regimen: A case of comparin…
Hua Li, Tong Li, Jun Wang, Qingtao Liang, Yun Zhang, et al.
BACKGROUND: ) lung disease remains far from satisfying. An effective regimen is needed to solve the problem. METHODS: lung disease who received antibiotics regimen at Beijing Chest Hospital Affiliated to Capital Medical University between July 1, 2010, and February 1, 2018. Patie…
Dhondiba Haribhau Bhise
…tum smear conversion in daily versus intermittent treatment regimens in diagnosed cases of new sputum smear-positive pulmonary tuberculosis patients. METHODS This retrospective observational study was carried out in the Department of Respiratory medicine and nodal drug resistance…
Kort F, Fournier Le Ray L, Chauffour A, Jarlier V, Lounis N, et al.
…nds supervising the treatment of tuberculosis. Intermittent regimens have the potential to simplify the supervision and improve compliance. Our objective was to analyse the sterilising activity of once-weekly regimens based on drugs with a long half-life, bedaquiline and rifapent…
Hassane-Harouna S, Cherif GF, Ortuno-Gutierrez N, Cisse D, Camara LM, et al.
Setting Since August 2016, after the Ebola outbreak, the Guinean National Tuberculosis Programme and Damien Foundation implemented the shorter treatment regimen (STR) for multidrug-resistant tuberculosis (MDR-TB) in the three MDR-TB sites of Conakry. Previously, the longer regime…
Wolfe A, Jadhav P, May A, Seymour S, Blanchard A, et al.
…d with each regimen. Overall, rifampin-containing shortened regimens are the preferred modality for LTBI treatment. A recent study in 2023 evaluated adherence and tolerance of the isoniazid(INH) + rifapentine(RPT), or "3HP" regimen and identified patient groups that may be at hig…
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, et al.
…evelopers aware of both the important features of treatment regimens, and patient and programmatic needs at the country level. In view of recent ground-breaking advances in tuberculosis treatment, WHO has revised and updated these regimen profiles. We used a similar process as fo…
Sulis G, Tavaziva G, Gore G, Benedetti A, Solomons R, et al.
…mide (2HRZE/10HR). The comparative effectiveness of shorter regimens is unknown. Methods To inform a WHO guideline update, we undertook a systematic review and meta-analysis to evaluate outcomes from regimens of 6- to less than 12-months' duration that included, at a minimum, iso…
Muniyandi M, Karikalan N, Velayutham B, Rajsekar K, Padmapriyadarsini C
Globally efforts are underway to shorten the existing 6-month tuberculosis (TB) treatment regimen for drug-sensitive patients, which would be equally effective and safe. At present, there is a lack of evidence on the cost implications of a shorter 4-month TB regimen in India. Thi…
Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.
…s (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Markov model to estimat…
Rashmi Ratnam, Roli Kushwaha, Parul Jain, Amita Jain
…tuberculosis (DR-TB), introduced two bedaquiline-containing regimens endorsed by the WHO for Rifampicin-resistant/Multi-drug resistant tuberculosis (RR/MDR TB). This study assesses clinical and microbiological outcomes of these regimens in RR/MDR TB patients. <bold>Material & Met…
Vijay Kumar, Upinder Kaur, Mohit Bhatia, Jaya Mishra
<bold>Introduction:</bold> Real-world evidence on oral regimens for drug-resistant tuberculosis (DR-TB) is scarce. <bold>Aims and objectives:</bold> To assess culture conversion at 6 months and adverse events (AEs) with oral regimens of DR-TB. <bold>Methods:</bold> A prospective …
Е. А. Бородулина, М.В. Ураксина, E. P. Еremenko, T. M. Larionova, A. N. Gerasimov
…tment method seems relevant. Aim: To analyze the prescribed regimens and the reason for their correction in newly identified patients before verifying the diagnosis of tuberculosis. Material and Methods. The following methods were used to detect MBT: luminescent microscopy, molec…
Ge Q, Ma Y, Zhang L, Ma L, Zhao C, et al.
…ate, adverse reaction rate, and recurrence rate between two regimens. Multivariate Cox regression model was used to identify the potential risk factors for recurrence after successful treatment with proportional hazards assumptions tested for all variables. Results A total of 381…
Musisi E, Wyness A, Eldirdiri S, Dombay E, Mtafya B, et al.
…andard-of-care and experimental anti-tuberculosis treatment regimens on the respiratory microbiome and implications for treatment outcomes. Methods In this retrospective study, we analysed the sputum microbiome of participants with tuberculosis treated with six experimental regim…
Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.
…und New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. F…
Mbelele PM, Mbelele PM, Mpolya EA, Sauli E, Mtafya B, et al.
…erculosis (RR/MDR-TB) treatment has largely transitioned to regimens free of the injectable aminoglycoside component, despite the drug class' purported bactericidal activity early in treatment. We tested whether Mycobacterium tuberculosis killing rates measured by tuberculosis mo…
Alexander Berg, James Clary, Debra Hanna, Eric L. Nuermberger, Anne J. Lenaerts, et al.
…necessitating the development of new and improved treatment regimens. Non-clinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in pro…